J. Wagnon

发表

Conformational preferences and self-association modes of two diastereomeric statine derivatives.

V. Barone, C. Toniolo, F. Fraternali, 2009, International journal of peptide and protein research.

Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.

J. Maffrand, J. Wagnon, G. Le Fur, 2002, Progress in brain research.

Biochemical and Pharmacological Properties of SR 49059 , a New , Potent , Nonpeptide Antagonist of Rat and Human Vasopressin Via Receptors

Ala, C. S. Gal, S., 2022 .

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

C. S. Gal, J. Maffrand, J. Wagnon, 1993, The Journal of clinical investigation.

Retrospective French nationwide survey of childhood aggressive vascular anomalies of bone, 1988-2009

Y. Révillon, I. Pin, L. Boccon-Gibod, 2010, Orphanet journal of rare diseases.

Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand.

J. Wagnon, C. Serradeil-Le Gal, M. Pascal, 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

CNS Drug Reviews

C. S. Gal, G. Griebel, J. Wagnon, 2005 .

Conformational analysis of pepstatin and related renin inhibitors by 400 MHz 1H n.m.r. spectroscopy.

M. Delepierre, B. Roques, J. Wagnon, 2009, International journal of peptide and protein research.

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

G. Griebel, J. Simiand, P. Soubrié, 2002, The Journal of pharmacology and experimental therapeutics.

Synthesis of indolyloxypropanolamines bearing the 2-(1H-indol-3yl)-1,1-dimethylethyl group: structure—activity studies and anti-hypertensive activity

J. Wagnon, P. Gautier, C. Lacour, 1988 .

Unsymmetrical cyano-cuprates as reagents in substitution and addition reactions

J. Wagnon, J. Levisalles, L. Hamon, 1973 .

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders

G. Griebel, J. Simiand, P. Soubrié, 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2.pi. + 6.pi.] Cycloaddition reactions between ligands coordinated to an iron atom

Raymond E. Davis, J. Wagnon, T. Hseu, 1974 .

Key amino acids located within the transmembrane domains 5 and 7 account for the pharmacological specificity of the human V1b vasopressin receptor.

C. S. Gal, D. Rognan, G. Guillon, 2004, Molecular endocrinology.

The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations

C. S. Gal, G. Guillon, S. Stoev, 2004, Journal of neuroendocrinology.

An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.

G. Griebel, J. Wagnon, R. Roux, 2006, CNS drug reviews.

SOME ASPECTS OF CONCERTED REACTIONS IN ORGANOMETALLIC SYSTEMS

J. Wagnon, R. Pettit, J. Wristers, 1974, Annals of the New York Academy of Sciences.